Emerging role of P53, Bcl-2 and telomerase activity in Egyptian breast cancer patients

IUBMB Life

Volumn 56, Issue 8, 2004, Pages 483-490

  Swellam, Menha ^a,e   Ismail, Manal ^b   Eissa, Sanaa ^c   Hamdy, Mohamed ^b   Mokhtar, Nadia ^d  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d CAIRO UNIVERSITY   (Egypt)

^e MAKERERE UNIVERSITY   (Uganda)

Author keywords

Apoptosis; bcl 2; Mutant p53; Oncogenes; Prognostic factors; Telomerase activity

Indexed keywords

PROTEIN BCL 2; PROTEIN P53; TELOMERASE;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; BREAST DISEASE; CANCER RECURRENCE; CARCINOGENESIS; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; EGYPT; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; ONCOGENE; POLYMERASE CHAIN REACTION; PROGNOSIS; TELOMERIC REPEAT AMPLIFICATION PROTOCOL;

ADOLESCENT; ADULT; AGE FACTORS; AGED; APOPTOSIS; BIOLOGICAL MARKERS; BLOTTING, WESTERN; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, PROGESTERONE; RECURRENCE; REGRESSION ANALYSIS; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9644265281     PISSN: 15216543     EISSN: None     Source Type: Journal    
DOI: 10.1080/15216540400010834     Document Type: Article

References (50)

1. El-Balkiny, M. (1991) General pathology of cancer. In: General Pathology of Cancer (El-Balkainy, ed.). Al-Sadekaa Graphics Center (AGC), Cairo.
2. Wyllie, A. H. (1995) The genetic regulation of apoptosis. Curr. Opin. Genet. Dev. 5, 9-104.
3. Tenz, G., London, L., Hockenbery, D., Alexander, M., Mckearn, J. P., and Prsmeyer, S. J. (1990) Deregulated bcl-2 gene expression selectively prolongs survival of growth factor deprived hemopoietic cell lines. J. Immuno. 52, 3602-3610.
4. Minler, A. E., Gregory, C. D., Jackman, G. W., Aherne, G. W., Dive, C., and Hichman, J. A. (1993) Bcl-2 modulation of apoptosis produced by anti-cancer drugs: resistance pathways. Cancer Res. 53, 3320-3326.
5. Lu, Q. L., Poulsom, R., Wong, L., and Hanby, A. M. (1993) Bcl-2 expression and embryonic non-haematopoietic tissues. J. Pathol. 169. 431-437.
6. Johnston, S. R., Salter, J., and Maclennan, K. (1992) Short- term tamoxifen induces the cytoplasmic expression of c-erb-B2 and Bcl-2 in ER-positive human primary breast cancer. Breast 3, 166-169.
7. Elledge, R. M., Green, S., Howes, L., Clark, G. M., Berardo, M., Allred, D. C., Pugh, R., Ciocca, D., Ravdin, P., Sullivan, J. O., et al. (1997) Bcl-2, p53 and Response to tamoxifen in Estrogen Receptor-Positive metastatic Breast Cancer: A southwest oncology group study. J. Clin. Oncol. 15, 1916-1922.
8. Yonish-Rouach, E., Renitsky, D., Lotem, J., et al. (1991) Wild type p53 induces apoptosis of myeloid leukemia cells that is inhibited by interlukin-6. Nature 352. 354-347.
9. Lotem, J., and Sachs, L. (1993) Regulation by Bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in different complement and defective myeloid leukemic cells. Growth Diff. 3, 41-47.
10. Morin, G. B. (1989) The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 59, 521-529.
11. Shay, J. W., and Bacchetti, S. (1997) A survey of telomerase activity in human cancer. Europ. J. Cancer 33, 787-791.
12. Am Joint Committee on Cancer (AJCC). (1992) Manual for Staging of Cancer (4th edn.) J. B. Lippincott Co., Philadelphia, USA.
13. Eissa, S., and Seada, L. (1999) Quantitation of bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with western blot and immunohistochemistry. Clinical Chemistry 44(7), 1423-1429.
14. Bradford, M. M. (1976) Rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem. 722. 28-251.
15. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular cloning (3rd edn.) Cold Spring Harbor: Laboratory 18, 42-59.
16. Kim, N. W., Piatyszek, M. A., Prowes, K. R., Harley, C. B., West, M. D., et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015.
17. Henderson, R. (1993) Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann. Clin. Biochem. 30, 512-539.
18. McGee, D. E. (1989) Epidemiologic programs for computers and calculators. A program for logistic regression on the IBM PC. Am. J. Epidemiol. 124, 702-705.
19. Abbott Laboratories Diagnostic Division. (1984) Abbott ER-EIA Monoclonal package insert.
20. Abbott Laboratories Diagnostic Division. (1984) Abbott PR-EIA Monoclonal package insert.
21. Page, D. L. (1991) Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am. J. Surg. Pathol. 15, 334-349.
22. Jordan, K., and Lippman, M. E. (1994) Overview of the biologic markers in breast cancer. Hematol. Oncol. Clin. North Am. 8, 73-100.
23. Johanston, S. R. D., MacLennan, K. S., Sacks, N. P. M., Salter, J., Smith, I. E., and Dowsett, M. (1994) Modulation of bcl-2 and ki-67 expression in estrogen-positive human breast cancer by tomoxifen. Eur. J. Cancer 11, 1662-1669.
24. Hellemans, P., Van Dam, P. A., Weyler, J., Van Osterom, A. T., Buytaert, P., and Van Marck, E. (1995) Prognostic value of bcl-2 expression in invasive breast cancer. British J. Cancer 72, 354-360.
25. Baba, M., Hideshima, T., Shinohara, T., Yamashital, J. I., and Shirakusa, T. (1996) Immunohistochemical analysis of bcl-2 and p53 protein in breast carcinoma. Int. J. Oncol. 8. 355-358.
26. Charpin, C., Andrac, L., and Vacheret, H., et al. (1998) Multi-parametric evaluation (SAMBA) of growth fraction (monoclonal ki 67) in breast carcinoma: a correlation of immunodetection in tissue sections and morphological data and estrogen and progesterone receptor immunocytochemical assays. Cancer Res. 48, 4368-4374.
27. Biroccio, A., Candiloro, A., Mottolese, M., Sapora, O., Albini, A., Zui, G., and Del Bufalo, D. (2000) Bcl-2 over-expression and hypoxia synergistically act to modulate VEGF expression and in vivo angiogenesis in a breast cancer cell line. FASEB J. 14, 652-660.
28. El-Ahmady, O., El-Salahy, E., Mahmoud, M., Abdel Wahab, M., Eissa, S., and Khalifa, A. (2002) Multivariate analysis of Bcl-2, Apoptosis, p53 and Her-2/neu in breast cancer: A short-term follow-up. Anticancer Res. 22, 2493-2500.
29. Walker, R. A., Dearing, S. J., Lane, D., and Valley, J. M. (1991) Expression of p53 protein in infiltrating and in situ breast carcinomas. J. Pathol. 165, 203-211.
30. Gursan, N., Karakok, M., Sari, I., and Gursan, M. S. (2001) The relation Ship between the expression of p53/ Bcl-2 and histopathological criteria in breast invasive ductal carcinomas. Int. J. Clin. Pract. 55(9), 589-590.
31. Younes, M., Lebovitz, R. M., Bommer, K. E., Morion, D., Khan, S., and Laucirice, R. (1995) p53 accumulation in benign breast biopsy specimens. Hum. Pathol. 26, 155-158.
32. Rohan, T. E., Hartwick, W., Miller, A. B., and Kandel, R. A. (1998) Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J. Natl. Cancer Inst., 90(17), 1247-1248.
33. Shay, J. W., and Wright, W. E. (1996) The reactivation of telomerase activity in cancer progression. Trends Genet. 12, 129-131.
34. Hiyama, E., Saeki, T., Hiyama, K., Takashima, S., Shay, J. W., Matsuura, Y., and Yokoyama, T. (2000) Telomerase activity as a marker for breast carcinoma in fine needle aspirated samples. Cancer Cytopathol. 90, 235-238.
35. Yashima, K., Milchrub, S., Gollahon, L. S., Miatra, A., Saboorian, M. H., Shay, J. W., and Gazdar, A. F. (1998) Telomerase enzyme activity and RNA expression during the multistage pathogenesis of breast carcinoma. Clin. Cancer Res. 4(1), 229-234.
36. Greaves, M. (1996) Is telomerase activity in cancer due to selection of stem cells and differentiation arrest? Trends Genet. 12, 127-128.
37. Steck, K., McDonnell, T. J., and El-Naggar, A. K. (1995) Flowcytometric analysis of apoptosis and Bcl-2 in human solid neoplasm. Cytomety 20, 154-161.
38. Montero, S., Guzman, C., Vargas, C., Ballestin, C., Cortes-Funes, H., and Colomer, R. (2001) Prognostic value of cytosolic p53 protein in breast cancer. Tumor Biol. 22(5), 337-344.
39. Domagala, W., Welcjer, M., Chosia, M., Karbowniczek, M., Harezga, B., Bartkova, J., Bartek, J., and Osborn, M. (2001) P21/WAF1/CIP1 expression in invasive ductal breast carcinoma: relationship to p53, proliferative rate and survival at 5-years. Virchows Arch. 239(2), 132-140.
40. Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angle, L. S., Santee, S. M., Fujiwara, T., Kruzel, E., and Radinsky, R. (1995) Wild-type human p53 and a temperature sensitive mutant induce fas/APO1 expression. Mol. Cell. Biol. 15, 3032-3040.
41. Scott, P. A. E., Smith, K., Poulsom, R., DeBenedetti, A., Bicknell, R., and Harris, A. L. (1998) Differential expression of VEGF mRNA vs. protein isoform expression in human breast cancer and relation ship to eIF-4E. Br. J. Cancer 77, 2120-2128.
42. Greider, C. W. (1994) Mammalian telomerase dynamics: healing, fragmentation shortening and stabilization. Curr. Opin. Genet. Dev. 4. 203-211.
43. Simickova, M., Nekulova, M., Pecen, L., Cernoch, M., Vagundova, M., and Pacovsky, Z. (2001) Quantitative determination of telomerase activity in breast cancer and benign breast diseases. Neoplasma 48(4), 267-273.
44. Miyashita, T., and Reed, J. C. (1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80, 293-299.
45. Mueller, C., Riese, U., Koosmehl, H., Dahse, R., Claussen, U., and Ernst, G. (2002) Telomerase activity in microdissected human breast cancer tissues: association with p53, p21 and outcome. Int. J. Oncol. 20(2), 385-390.
46. Harley, C. B. Telomeres and aging. In: Telomeres (Blackburn E. H and Greider C. W. eds). p247. Cold Spring Harbor Laboratory Press, Plainview, NY.
47. Wynford-Thomas, D. (1997) Proliferative life span checkpoints: cell-type specifically and influence on tumor biology. Eur. J. Cancer 33, 716-726.
48. McGuire, W. L., Tandon, A. K., Allerd, D., Chamness, G. C. and Clark, G. M. (1992) Breast cancer update: Prognostic profile markers. Division of specialty lab. INC. How to use prognostic factors in ANN breast cancer patients. J. Natl. Cancer Inst. 82, 1451-1453.
49. Hsu, B., Marin, M. C., Brisby, S., McConnel, K., and McDonnell, T. J. (1994) Expression of bcl-2 gene confers multidrug resistance to chemotherapy-induced cell death. Cancer Bull. 46, 125-129.
50. Melena, S. M., Holl, J. F., and Pogo, B. (1998) Inhibition of cell growth, and telomerase activity of breast cancer cells in vitro by zidovudine. Clin. Cancer Res. 89, 1874-1881.